Pharmacokinetic Evaluation of Two Paclitaxel-Coated Balloons with Different Drug Load in a Short-Term Porcine Study

被引:6
作者
Abadal, J. M. [1 ]
Vazquez, Esther [2 ]
Morales, Miguel [1 ]
Toro, Arturo [1 ]
Quintana, Manuel [2 ]
Araujo, Miguel [2 ]
机构
[1] Hosp Univ Severo Ochoa, Vasc & Intervent Radiol Dept, Madrid 28911, Spain
[2] Hosp Univ Severo Ochoa, Dept Vasc Surg, Madrid, Spain
关键词
Drug-coated balloons; Angioplasty; Paclitaxel; Neointimal hyperplasia; MUSCLE-CELL-PROLIFERATION; ELUTING BALLOON; RESTENOSIS; STENTS; MODEL; ANGIOPLASTY; PREVENTION; MIGRATION; DELIVERY; ARTERIES;
D O I
10.1007/s00270-016-1346-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to evaluate the pharmacokinetics and tissue absorption of 2 paclitaxel (PTX) drug-coated balloons (DCB) using different drug loads in a porcine-injured iliac artery model. Twenty-eight pigs were randomized into 2 groups. In group B1, angioplasty was performed with a 1.0 A mu g/mm(2) DCB with PTX and in group B3, with a 3.0 A mu g/mm(2) DCB with PTX. An overstretched model of the iliac artery was used for angioplasty under fluoroscopy. Blood and vessel wall PTX were measured with liquid-chromatography mass spectrometry at 1, 5, 30 min, 1, 7, and 28 days. Remaining drug in the balloon was analyzed. Mean PTX in blood was significantly higher in the group B3 0.269 +/- A 0.085 A mu g/ml compared with the B1 0.218 +/- A 0.085 A mu g/ml; p = 0.01. Peak blood PTX concentration was detected at 1 min, and PTX was undetectable 24 h post-angioplasty. There were no statistically significant differences in the mean arterial wall concentration from the treated iliac artery between group-B1 (15.24 +/- A 21.29 ng/mg) and B3 (15.68 +/- A 16.33 ng/mg), or in the PTX wall concentration measured at different time points. Mean remaining drug in assayed balloons was lower for group-B1 and represented 8 % of the initial dose. Blood PTX was higher when using 3.0 A mu g/mm(2) DCB, with a peak drug concentration at 1-min, although the drug was undetectable at 24 h, independently of the loading dose. This study demonstrates no difference in arterial wall uptake of a low dose DCB (1.0 A mu g/mm(2)), when compared to a common dose DCB (3.0 A mu g/mm(2)) suggesting that the dose of drug in the DCB could be reduced obtaining a similar clinical effect.
引用
收藏
页码:1152 / 1158
页数:7
相关论文
共 23 条
[11]   Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter [J].
Oberhoff, M ;
Kunert, W ;
Herdeg, C ;
Küttner, A ;
Kranzhöfer, A ;
Horch, B ;
Baumbach, A ;
Karsch, KR .
BASIC RESEARCH IN CARDIOLOGY, 2001, 96 (03) :275-282
[12]   Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteries [J].
Parry, TJ ;
Brosius, R ;
Thyagarajan, R ;
Carter, D ;
Argentieri, D ;
Falotico, R ;
Siekierka, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 524 (1-3) :19-29
[13]   Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival - Role of AKT-dependent signaling [J].
Patterson, Cam ;
Mapera, Sabeen ;
Li, Hui-Hua ;
Madamanchi, Nageswara ;
Hilliard, Eleanor ;
Lineberger, Rob ;
Herrmann, Robert ;
Charles, Peter .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (07) :1473-1480
[14]   Optimization of Drug-Eluting Balloon Use for Safety and Efficacy: Evaluation of the 2nd Generation Paclitaxel-Eluting DIOR-Balloon in Porcine Coronary Arteries [J].
Posa, Aniko ;
Nyolczas, Noemi ;
Hemetsberger, Rayyan ;
Pavo, Noemi ;
Petnehazy, Oers ;
Petrasi, Zsolt ;
Sangiorgi, Giuseppe ;
Gyoengyoesi, Mariann .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2010, 76 (03) :395-403
[15]   Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients [J].
Radke, Peter W. ;
Joner, Michael ;
Joost, Alexander ;
Byrne, Robert A. ;
Hartwig, Sonja ;
Bayer, Gerd ;
Steigerwald, Kristin ;
Wittchow, Eric .
EUROINTERVENTION, 2011, 7 (06) :730-737
[16]   The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus Uncoated Balloon Angioplasty [J].
Scheinert, Dierk ;
Scheinert, Dierk ;
Duda, Stephan ;
Zeller, Thomas ;
Krankenberg, Hans ;
Ricke, Jens ;
Bosiers, Marc ;
Tepe, Gunnar ;
Naisbitt, Scott ;
Rosenfield, Kenneth .
JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (01) :11-19
[17]   Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis [J].
Scheller, B ;
Speck, U ;
Abramjuk, C ;
Bernhardt, U ;
Böhm, M ;
Nickenig, G .
CIRCULATION, 2004, 110 (07) :810-814
[18]  
Scheller B, 2011, HERZ, V36, P232, DOI 10.1007/s00059-011-3462-3
[19]   Preclinical restenosis models and drug-eluting stents - Still important, still much to learn [J].
Schwartz, RS ;
Chronos, NA ;
Virmani, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (07) :1373-1385
[20]   In vitro estimation of drug loss during the implantation procedure of drug-eluting stents [J].
Seidlitz, A. ;
Nagel, S. ;
Semmling, B. ;
Petersen, S. ;
Reske, T. ;
Schmidt, W. ;
Grabow, N. ;
Sternberg, K. ;
Weitschies, W. .
BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE TECHNIK, 2012, 57 :403-406